Novavax CEO Mr. Stanley Erck believes that the vaccine’s earliest approvals are likely to be accorded abroad and that the company has applied in UK, EU, Korea and India.
According to Indian sources, India can take a cue from the UK regulator but may proceed on the basis of strong interim data.
According to the Indian government projections, 200 million Novavax shots can be available during September to December 2021.
Novavax, named Covavax in India, is in advanced stages of Phase 2/3 “observer-blinded, randomized, active-controlled” bridging trials with Serum Institute of India enrolling 1,600 adult participants SII has also indicated an interest in conducting trials in children, official sources said. It may well be possible that India becomes the first country for the launch of the vaccine.
The company is already engaged with SII for supplies and is doing trials with Indian Council for Medical Research.
Novavax Inc (NVAX.O) on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial. The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.
Last updated: December 26th, 2025
